Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 studyResearch in context
Summary: Background: Vaccines that minimize the risk of vaccine-induced antibody-dependent enhancement and severe dengue are needed to address the global health threat posed by dengue. This study assessed the safety and immunogenicity of a gold nanoparticle (GNP)-based, multi-valent, synthetic pept...
Main Authors: | Alix Miauton, Régine Audran, Juliette Besson, Hélène Maby-El Hajjami, Maxime Karlen, Loane Warpelin-Decrausaz, Loredana Sene, Sylvain Schaufelberger, Vincent Faivre, Mohamed Faouzi, Mary-Anne Hartley, François Spertini, Blaise Genton |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-01-01
|
Series: | EBioMedicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396423004887 |
Similar Items
-
Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines
by: Vannice, Kirsten S., et al.
Published: (2018) -
Clinical development update: 1st dengue vaccine candidate
by: Alain Bouckenooghe
Published: (2016-02-01) -
Molecular identification of dengue virus binding protein on filopodia of vero cells
by: Aliyu, Isah Abubakar
Published: (2017) -
Safety and immunogenicity of a single dose, live-attenuated ‘tetravalent dengue vaccine’ in healthy Indian adults; a randomized, double-blind, placebo controlled phase I/II trial
by: Lalitendu Mohanty, et al.
Published: (2022-04-01) -
Moving forward with Takeda's live chimeric tetravalent dengue vaccine
by: Wilder-Smith, Annelies
Published: (2017)